NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE’S REPUBLIC OF CHINA, SOUTH AFRICA, NEW ZEALAND, JAPAN OR THE UNITED STATES, OR ANY OTHER JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL.
Reference is made to the stock notice from SoftOx Solutions AS (the “Company”) on 14 August 2025 regarding the financing facility with Long State Investments Limited.
…
Vis børsmeldingen
Softox Solutions AS (“SoftOx”) today announces that the board of directors has resolved a private placement at a subscription price of NOK 0.0725, with Long State subscribing for 45 000 000 shares in the Company. The subscription price corresponds to the procedure outlined in the Equity Placement Agreement. In accordance with the financing facility, Long State received a placement commission on market terms.
Following the private placements, the new share capital of the Company will be NOK 48 708 339.88 divided into 2 435 416 994 shares, each with a par value of NOK 0.02.
For more information on the financing facility, please see the Company’s stock exchange release dated 14 August 2025.
Deviation from shareholders’ preferential rights
The board of directors has considered the private placement in light of the equal treatment principles under the Norwegian Securities Trading Act and Oslo Børs’ Oslo Rule Book II – Membership and Trading Rules and Oslo Børs’ Circular no. 2/2014, and is of the opinion that the waiver of the preferential rights inherent in the following private placement is considered necessary in the interest of time and successful completion in order to secure funding of SoftOx. Taking into consideration the time, costs, and expected terms of alternative methods of securing the necessary funding, the board of directors concluded that the completion of the private placements, including the waiver of the preferential rights inherent to the private placements, is in the common interest of the shareholders of SoftOx. Further, the board assessed whether a subsequent offering should be carried out. As the private placement is limited and considering the cost inherent in a subsequent offering, the board concluded that a subsequent offering shall not be carried out.
For further information, please contact:
Ulrik Spork, COB Soft Solutions AS, +45 31 38 83 87
Ingrid Juven, CFO SoftOx Solutions AS, +47 918 76 165
Mail: ir@soft-ox.com
About SoftOx Solutions AS: SoftOx Solutions AS (ticker: SOFTX) is a clinical-stage pharmaceutical company listed on Euronext Growth Oslo. The company is developing highly effective pan-antimicrobial pharmaceuticals targeting bacteria, viruses, and fungi. The technology is based on extensive research and development in partnership with leading Nordic research institutes.
Kilde
